| 条款 | 修订前 | | 修订后 | | --- | --- | --- | --- | | 公司章程第一 | 董事会由七名董事组成，其中独立董事三名。 | | 董事会由不低于七名董事组成，独立董事占 | | 百一十条 | | | 董事会成员的比例不得低于三分之一。 | | 议事规则第八 | 公司董事会由 7 名董事组成，设董事长 人 | 1 | 董事会由不低于七名董事组成，设董事长一 | | 条 | 董事会成员中应当有三分之一以上独立董 | | 人，独立董事占董事会成员的比例不得低于 | | | 事，其中至少一名为会计专业人士。 | | 三分之一，且至少包括一名会计专业人士。 | 本次《公司章程》修订须经公司股东会审议批准后生效，并提请股东会授权 董事会办理工商变更登记等相关事项。修订后的事项最终以工商部门登记备案结 果为准。 广州万孚生物技术股份有限公司 广州万孚生物技术股份有限公司章程修订案（2025 年 12 月） 广州万孚生物技术股份有限公司（以下简称"公司"或"万孚生物"）根据 实际情况就《广州万孚生物技术股份有限公司章程》（以下简称"公司章程"）及 其附件《广州万孚生物技术股份有限公司董事会 ...

1、本次股东大会无增加、变更提案的情况。 证券代码：300482 证券简称：万孚生物 公告编号：2025-079 广州万孚生物技术股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 重要提示： 2、本次股东大会以现场投票和网络投票相结合的表决方式。 3、本次股东大会未涉及变更前次股东大会决议的情形。 4、中小投资者是指除上市公司董事、监事、高级管理人员以及单独或者合计持有公司 5%以上股份 的股东以外的其他股东 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、部门 规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 01 月 14 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 01 月 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-081 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于高级管理人员辞任暨选举职工代表董事的公告 1、公司 2025 年第一次职工代表大会会议决议； 二、选举职工代表董事情况 根据《广州万孚生物技术股份有限公司章程》的规定，公司董事会由 7 名董 事组成，设职工代表董事 1 名。职工代表董事由公司职工通过职工代表大会、职 工大会或者其他形式民主选举产生，无需提交股东会审议。公司于 2025 年 12 月 29 日召开了 2025 年第一次职工代表大会，经全体与会职工代表表决，同意选 举康可人女士（简历详见附件）为第五届董事会职工代表董事，康可人女士与第 五届董事会非职工代表董事共同组成第五届董事会，任期自本次职工代表大会选 举通过之日起至公司第五届董事会任期届满之日止。 康可人女士符合《中华人民共和国公司法》等相关法律法规及《公司章程》 1 规定的有关董事任职资格和条件。本次选举完成后，董事会中兼任公司高级管理 人员以及由职工代表担任的董事人数总 ...

Core Viewpoint - Guangzhou Wanfu Biological Technology Co., Ltd. has received a medical device registration certificate from the National Medical Products Administration for its fully automated nucleic acid purification and real-time fluorescence PCR analysis system, enhancing its product offerings in the nucleic acid testing field [1] Group 1: Product Approval and Features - The newly approved system integrates magnetic bead nucleic acid extraction and real-time fluorescence PCR detection technology, enabling fully automated operations from sample processing to result output [1] - The product addresses the clinical demand for rapid pathogen detection and human gene analysis, providing efficient and convenient testing solutions for medical institutions [1] Group 2: Product Line Expansion - The approval of the nucleic acid testing system, along with the recently certified test kits for adenovirus, mycoplasma pneumoniae, and parainfluenza virus, expands the company's product line in the nucleic acid testing sector [1] - The product suite now covers common respiratory pathogens, including influenza A and B viruses, respiratory syncytial virus, adenovirus, mycoplasma pneumoniae, and parainfluenza virus, meeting the rapid screening needs for high-incidence respiratory infectious diseases [1] Group 3: Strategic Impact - The acquisition of the medical device registration certificate enhances the company's core competitiveness and market expansion capabilities, positively impacting its development [1] - The company plans to actively promote the sales of the newly approved products [1]

Group 1 - Guangdong Construction signed an EPC contract worth 416 million yuan, with a total construction area of 99,595.6 square meters and a construction period of 640 calendar days [1] - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [2] - Jinbei Automotive signed a memorandum of understanding with E-Works to establish a research and development center for electric light commercial vehicles [3] Group 2 - Hongsheng Huayuan is expected to win approximately 569 million yuan in procurement projects from the State Grid, which represents about 5.61% of the company's projected revenue for 2024 [4] - Zhongding Co. plans to establish a joint venture for humanoid robot manufacturing with a registered capital of 50 million yuan [5] - Kede CNC's new factory in Shenyang is expected to achieve an annual production capacity of about 60 units [6] Group 3 - Hongbo Pharmaceutical's share transfer price is set at 25.27 yuan per share [7] - ST Jinglan plans to sign a letter of intent for the acquisition of Xinlian Environmental Technology Co., enhancing its core technology competitiveness [8][9] - Hato Co. announced the resignation of its general manager due to job relocation [10] Group 4 - Meibang Co. plans to apply for a new bank credit line of up to 160 million yuan [11] - Southern Media's general manager resigned due to job relocation [12] - Dalian Electric Porcelain's subsidiary is expected to win procurement projects from the State Grid worth approximately 70.7 million yuan [13] Group 5 - Sinopharm Modern's subsidiary received a drug registration certificate for a new medication [14] - ST Meigu plans to implement a capital reserve transfer to increase share capital, leading to a one-day stock suspension [15] - Ruisheng Intelligent confirmed a transaction of 152 million yuan for domestic computing equipment procurement [16] Group 6 - Jinguang Electric won three procurement packages from the State Grid, totaling 37.43 million yuan [17] - Guangju Energy increased its stake in Mawan Power to 14.42% by acquiring an 8% share for 680 million yuan [18][19] - ST Lingda announced a stock suspension due to capital reserve transfer related to its restructuring plan [20] Group 7 - Suli Co. plans to increase its investment in Suli Ningxia by 76.63 million yuan [21] - Dalian Shengya's subsidiary plans to reduce its registered capital by 32.37 million yuan [22] - Yinxin Technology received a cash dividend of 11.05 million yuan from its subsidiary [23] Group 8 - Haike New Source signed a three-year supply agreement for 270,000 tons of electrolyte materials [24] - Xinhua Medical received registration certificates for several medical devices [25] - Wantai Bio received a registration certificate for an HIV antibody testing kit [26] Group 9 - Beilu Pharmaceutical obtained a drug registration certificate for a new erectile dysfunction treatment [31] - Zhongwei Company is planning to issue shares to acquire assets, leading to a stock suspension [32] - Zhejiang Haideman plans to purchase land for strategic development, with a budget of up to 260 million yuan [33] Group 10 - Ningbo Ocean announced the resignation of its deputy general manager due to job adjustments [34] - Tongguang Cable is expected to win procurement projects from the State Grid worth over 139 million yuan [35]

Core Viewpoint - Wanfu Biology (300482) has received medical device registration certificates from the National Medical Products Administration for its products, indicating a significant advancement in its product offerings and regulatory compliance [1] Group 1 - The company announced the receipt of medical device registration certificates on December 25 [1] - The registered products include a fully automated nucleic acid purification and real-time fluorescence PCR analysis system [1] - Additionally, the company received approval for a nucleic acid testing kit for adenovirus, mycoplasma pneumonia, and parainfluenza virus using fluorescence PCR method [1]

Group 1 - The company Wanfu Bio announced on December 25 that its fully automated nucleic acid purification and real-time fluorescence PCR analysis system has received a medical device registration certificate from the National Medical Products Administration [1] - Additionally, the adenovirus/pneumonia mycoplasma/parainfluenza virus nucleic acid detection kit (fluorescence PCR method) has also been granted the same medical device registration certificate [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-076 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于取得产品注册证的公告 广州万孚生物技术股份有限公司（以下简称"万孚生物"或"公司"）近日 收到国家药品监督管理局颁发的医疗器械注册证，具体信息如下： | 名称 | | 注册证号 | | 适用范围 | 有效期至 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 本产品基于磁珠法核酸提取技术和实时荧光 PCR 检测原理，与配套的检测试剂共同使用，自动完 | | 全自动核酸提纯及 | | 国 械 注 准 | | | | 成从核酸提取纯化到扩增、检测一系列操作步 | | 实时荧光 PCR | 分析系 | 20253222465 | | | 2030/11/30 | 骤，在临床上对来源于人体样本中的靶核酸 | | 统 | | | | | | (DNA/RNA)进行定性/定量检测，包括病原体、人 | | | | | | | | 类 ...

Core Viewpoint - The fentanyl concept sector experienced a decline of 0.26% as of the market close on December 24, with several companies within the sector showing significant drops in stock prices [1] Market Performance - The top-performing concept sectors today included: - Terahertz: +4.02% - Commercial Aerospace: +3.60% - Satellite Navigation: +3.47% - Fentanyl: -0.26% [1] Fund Flow Analysis - The fentanyl concept sector saw a net outflow of 63 million yuan from main funds today, with six stocks experiencing significant outflows. The stock with the highest outflow was ST Renfu, which had a net outflow of 42.89 million yuan [1] - Other notable outflows included: - Enhua Pharmaceutical: -13.02 million yuan - Wanfu Biology: -5.15 million yuan - Botao Biology: -2.70 million yuan [1] - Conversely, the stocks with the highest net inflows included: - Guoyao Modern: +1.77 million yuan - Guoyao Shares: +1.47 million yuan [1] Individual Stock Performance - The following stocks within the fentanyl concept sector had notable price changes: - ST Renfu: -2.06% with a turnover rate of 1.92% - Enhua Pharmaceutical: -0.79% with a turnover rate of 0.68% - Wanfu Biology: +0.61% with a turnover rate of 0.51% - Botao Biology: -0.28% with a turnover rate of 0.74% - Guoyao Modern: +0.20% with a turnover rate of 0.51% [1]

Core Insights - The article discusses the registration and quality management system assessments for medical devices in Guangdong Province, highlighting various companies and their products that have undergone evaluations and received approvals or required modifications [2][5]. Group 1: Company Registrations - Guangdong Weinuodun Medical Technology Co., Ltd. received approval for its medical ozone therapy device on November 3, 2025 [3]. - Guangdong Baisheng Medical Instrument Co., Ltd. passed the evaluation for high-frequency surgical equipment on November 3, 2025 [3]. - Shenzhen Kefu Biotechnology Co., Ltd. was approved for its continuous glucose monitoring system on November 4, 2025 [3]. - Guangzhou Wanfu Biological Technology Co., Ltd. received approval for its hepatitis B virus nucleic acid testing kit on November 10, 2025 [3]. - Shenzhen Karman Medical Equipment Co., Ltd. was approved for its intracranial pressure sensor and cerebrospinal fluid drainage set on November 12, 2025 [3]. Group 2: Quality Management System Assessments - The Guangdong Provincial Drug Administration is implementing a quality management system assessment for Class II medical devices, with results communicated to applicants via SMS or web queries since May 2022 [5]. - Companies such as Shenzhen Aibo Hechuang Medical Robot Co., Ltd. received approval for their vascular intervention surgery control system on November 27, 2025 [5]. - Guangdong Tiancheng Tianmei Medical Technology Co., Ltd. was approved for absorbable surgical sutures on November 19, 2025 [4].